Sodium glucose cotransporter 2 (SGLT2) inhibitors are a relatively new class of anti-hyperglycaemic drugs with a unique mechanism of action. Some of the drugs in this class include dapagliflozin, canagliflozin, empagliflozin, tofogliflozin, ipragliflozin, and luseogliflozin.
| INTRODUC TI ON
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a relatively new class of anti-hyperglycaemic drugs with a unique mechanism of action. Some of the drugs in this class include dapagliflozin, canagliflozin, empagliflozin, tofogliflozin, ipragliflozin, and luseogliflozin.
This class of drugs exerts its pharmacological effect by inhibiting the sodium glucose cotransporter 2 proteins which are responsible for the reabsorption of glucose in the S1 segment of the proximal convoluted tubule of the nephron. The process of glucose resorption is elucidated in Figure 1 . This inhibition causes reduction in the renal threshold for glucose (RT G ) and diminution in its resorption, ultimately leading to excretion of glucose in the urine 1 ( Figure 2 ).
However, recent studies have found that this class of drugs has shown potential not only in the treatment of type 2 diabetes mellitus (T2DM), but also for the treatment of numerous other disorders (Tables 1 and 2 ). In this article, we will discuss the recent pre-clinical and clinical studies that elaborate upon the alternate pharmacological actions of SGLT2 inhibitors and encourage their use in various indications other than T2DM.
| EFFEC T OF SG LTINHIB ITOR S ON C ARDIOVA SCUL AR DISORDER S
Certain SGLT2 inhibitors such as empagliflozin have shown outstanding efficacy in reducing cardiovascular mortality. The Empagliflozin
Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus
Patients (EMPA-REG OUTCOME) reflected that the rate of hospital admissions due to congestive heart failure was 35% lower with empagliflozin in comparison to placebo. 2 An in vivo rodent study evaluating the efficacy of empagliflozin on diastolic dysfunction demonstrated that chronic treatment with empagliflozin ameliorates diastolic function, reduces myocardial insulin resistance and also preserves growth signalling pathways and handling of calcium.
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Even in case of impaired urinary excretion of glucose, such as in case of later stages of chronic kidney disease, it has been found that the extraglycemic effects of empagliflozin stay intact. A combination of mechanisms such as decreased renal lipid accumulation and intrarenal inflammation, reduced arterial stiffness, increased renal salt sensitivity, and effects via neurohormonal pathways may be responsible for the anti-hypertensive effect of SGLT2 inhibitors in spite of impaired kidney function. 4 In addition to empagliflozin, canagliflozin, another member of the SGLT2 family, has also shown favourable cardiovascular effect in a clinical study consisting of 666 patients of T2DM. It was observed that therapy with canagliflozin attenuated the levels of NT-proBNP and hsTnI which are established biomarkers with prognostic value for cardiovascular disorders, thereby indicating the cardioprotective value of canagliflozin. There was a surge in the levels of the aforementioned biomarkers in patients who were given the placebo which reflected an increased risk of cardiovascular disorders.
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A systematic review and meta-analysis based on 27 randomized control trials by Baker and colleagues concluded that SGLT2 inhibitors showed significant anti-hypertensive effects on both systolic as well as diastolic blood pressure in patients with T2DM. 2 Another meta-analysis by Pinto et al. 6 deduced that SGLT2 inhibitors are more potent in controlling systolic and diastolic blood pressure than corresponding anti-hyperglycaemic drugs of other classes such as metformin, sulphonylurea, and [7] [8] [9] There are several other hypotheses which try to delineate the favourable effects of SGLT2 inhibitors on the cardiovascular system such as diminution in oxidative stress and inflammation, increased natriuresis and diuresis, amelioration of arterial stiffness, etc. However, an increase in stroke risk observed with empagliflozin has been attributed to surge in hematocrit levels whereas canagliflozin has been associated with a higher amputation risk.
10,11
A multinational clinical trial including 309 056 patients reflected that there was a lower incidence of hospitalization due to heart failure in subjects treated with SGLT2 inhibitors in comparison to those being treated with other anti-hyperglycaemic drugs. 12 A further sub-analysis of this clinical trial data revealed that therapy with SGLT2 inhibitors was associated with a modestly reduced risk of myocardial infarction and stroke, which further bolstered the results obtained from the clinical trial pertaining to the cardiovascular actions of SGLT2 inhibitors, particularly ischemia. 13 Moreover, the use of SGLT2 inhibitors has also been proposed in the treatment of heart failure irrespective of the presence or absence of T2DM and several clinical studies are currently in progress to evaluate this prospect. 14 A clinical trial, known as the EMBLEM trial, intending to investigate the effect of empagliflozin on endothelial function in patients with established cardiovascular disease is currently underway in Japan (Unique Trial Number: UMIN000024502). 15 Another clinical study investigating the effect of SGLT2 inhibitors on diabetic atherosclerosis and subsequent cardiovascular disease using intima-media thickness as a marker of cardiovascular disease is also in progress (Unique Trial Number: UMIN000017607). 20 These results were concomitant with a previous study done on rodents via the streptozotocin-induced diabetes model.
| EFFEC T OF SG LT2 INHIB ITOR S ON HEPATIC D ISORDER S
Both studies also indicated a beneficial effect of ipragliflozin on liver injury probably as a result of reduction in levels of markers of hepatic oxidative stress and decline in levels of inflammatory markers in plasma. 21 In addition to ipragliflozin, dapagliflozin administration on uninephrectomized db/db mice led to amelioration of the alterations in hepatic production of myeloperoxidase as well as in other markers of oxidative stress and tissue inflammation. 22 Similarly, a study on a novel NASH rodent model by Jojima et al. 23 concluded that although empagliflozin is capable of exhibiting anti-inflammatory and anti-steatotic activities, administration of linagliptin in conjunction with empagliflozin is more efficacious in reversing NASH and shows stronger antfibrotic activity due to synergistic action. It has been suggested that the favourable pharmacological actions of SGLT-2 inhibitors in the treatment of hepatic steatosis is not only as a result of its insulin-independent anti-hyperglycaemic effect and caloric loss subsequent to glycosuria, but also because of their capability in balancing adipose and non-adipose tissues as well as in regulating energy homeostasis 24 Interestingly, tofogliflozin has demonstrated chemopreventive activity on diethylnitrosamine-induced hepatocellular carcinoma related to obesity in rats whereas canagliflozin has shown to attenuate hepatocellular carcinoma development in a non-alcoholic hepatic steatosis model in melanocortin 4 receptor-deficient mice induced via western diet.
24,25
An open-label, non-randomized clinical study involving 79 patients concluded that luseogliflozin significantly ameliorated alanine transaminase, aspartate transaminase, as well as γ-glutamyl transpeptidase levels in patients suffering from hepatic impairment in conjunction with T2DM. These results indicate towards the potential application of luseogliflozin in the therapy of T2DM patients with liver injury. 26 Another clinical study investigating the efficaciousness of canagliflozin in the treatment of patients with high alanine transaminase levels indicated a beneficial effect of canagliflozin in improving liver function.
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TA B L E 1 
TA B L E 1 (Continued)
TA B L E 2 3. Study does not take into consideration lifestyle or socioeconomic factors.
4. Dapagliflozin was much more extensively used in the study than other SGLT2 inhibitors.
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The aim of the study was to compare hospitalization for heart failure (HHF) & mortality in patients newly initiated on any SGLT2 inhibitor vs other glucose lowering drugs across 6 nations. The data for the study was collected from insurance claims, primary care & hospital records, and national registries from US, Sweden, Germany, Norway, United Kingdom, and Denmark. Data of 309 056 patients was used (Study
ID: NCT02993614)
Propensity score for SGLT-2 inhibitor initiation was used to match treatment groups. Hazard ratios for HHF, mortality, and their combination were ascertained by nation and combined to calculate weighted effect size Therapy with SGLT2 inhibitors was associated with lower rates of HHF, mortality, and HHF or mortality, with no significant heterogeneity by country 1. Possibility of residual, unmeasured confound cannot be excluded.
2. Other cardiovascular events like stroke or myocardial infarction were not evaluated.
3. Safety was not examined. 4. Long term study is needed to establish if therapy effects are sustained. 5. Different countries had different definitions of HHF.
6. Study did not focus on any mechanism of action of SGLT2 inhibitors.
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The study was conducted to investigate the effect of luseogliflozin therapy on HbA1c and hepatic function in T2DM patients. The study involved 79 patients (Study ID: UMIN000021584)
Patients were divided into 2 groups as per the levels of their hepatic function parameters -elevated group and normal group. Subjects were administered 2.5 mg luseogliflozin once daily. HbA1c, serum AST, ALT, γ-GTP, and serum lipid analyses were carried out prior to therapy, at 12 wk, and at 24 wk
Luseogliflozin administration led to significant improvements in HbA1c & body weight levels with no significant difference between normal & elevated groups. Pronounced reductions in serum AST, ALT, and γ-GTP levels were observed 1. Larger sample size would be required to draw concrete conclusions.
(Continues)

Study description
End point of the study/method
Results
Study limitations/comments
Reference no.
The aim of clinical study was to examine the effectiveness of canagliflozin (based on its effect on hepatic function and blood glucose levels) as well its safety in patients with high ALT (>30 U/L). It was a post hoc analyses of 3 previous studies (Study IDs: NCT010221122, NCT01413204, NCT01387737)
The improving actions on hepatic functionality, blood glucose levels, and safety achieved with 100 mg canagliflozin vs. placebo and for different ALT groups ie less than 30 U/L and more than 30 U/L were comparatively assessed. HbA1c, ALT, body weight, and adverse effects were evaluated Significant improvement in HbA1c levels and body weight were noted in both ALT groups in case of canagliflozin vs. placebo. Significant amelioration in ALT levels in high ALT group was also noted with canagliflozin & adverse effects observed were similar to the placebo group 1. Impaired hepatic function was defined as ALT >30 U/L. Patients with serious liver diseases or history of hepatitis B or hepatitis C were excluded. 2. Confirmed NAFLD was not present in all patients. 3. Alcohol intake was not regulated in the subjects.
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The objective of the study was to ascertain whether or not dapagliflozin improves endothelial function associated with a reduction in abdominal mass. 54 patients were involved in the study (Study ID: UMIN0000333354) γ-GTP, γ-glutamyl transpeptidase; ALT, alanine transaminase; AST, aspartate transaminase; CV, cardiovascular; hsTNI, high-sensitivity troponin I; LnRHI, natural logarithmic transformed value of the RH-PAT index; MI, myocardial infarction; NAFLD, non-alcoholic fatty liver disease; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RH-PAT, reactive hyperaemia peripheral arterial tonometry; sST2, soluble ST2.
TA B L E 2 (Continued)
| EFFEC T OF SG LT2 INHIB ITOR S ON OB E S IT Y
Because of the fact that SGLT2 inhibitors induce glycosuria, and generally do not cause hypoglycaemia, they have the potential to be used for controlling obesity and causing weight loss. Studies have confirmed that loss of weight due to SGLT2 inhibitor administration is caused due reduction in body fat mass and not because of any ulterior reasons (Table 1) . 1 An in vivo study on non-obese diabetic GotoKakizaki mice indicated that ipragliflozin promoted preferential loss of fat which was confirmed by dual-energy X-ray absorptiometry.
28
Another study on ipragliflozin also concluded that ipragliflozin treatment on diabetic rats led to reduction in body weight and diminution in epididymal adipose tissues. 20 There are several sources that corroborate the ability of SGLT2 inhibitors to cause weight loss and reduction in abdominal and total body fat, primarily adipose tissue.
A meta-analysis based on 39 randomized controlled trials concluded that SGLT2 inhibitors were more efficacious than placebo as well as metformin, sulphonylurea and DPP-4 inhibitors in reducing weight.
6
Another meta-analysis evaluating randomized control trials gave similar results. 29 However, in order to evaluate organ-specific variations in fat content, a randomized, double-blind, placebo controlled, cross trial (ENERGIZE)-study is currently in progress in which dapagliflozin is being used as the test drug.
30
Obesity and T2DM have often been associated with inflammation in various systemic organs. In a rodent study on C57BL/6J mice fed with high fat diet, it was observed that canagliflozin led to reductions in subcutaneous and visceral fat as well as body and liver weight. Furthermore, it was also observed that canagliflozin ameliorated accumulation of macrophages, inflammatory cytokine levels, as well as attenuated the surged mRNA levels of atrophic factor atrogin-1. 31 Similar results were also observed in another study investigating empagliflozin. 32 There are several schools of thought regarding the mechanism by which SGLT2 inhibitors lead to weight loss. For example, in a study involving high-fat-diet-induced obese rats, it was observed that ipragliflozin led to a surge in fatty acid oxidation and lipolysis whereas it reduced heat production rate from glucose and augmented the same from fat. 33 Ipragliflozin has also F I G U R E 3 Summary of different pharmacological actions of SGLT2 inhibitors and their consequent therapeutic actions found to be effective in controlling obesity in type 2 diabetic mice fed sugar solution which represents its anti-obesity efficacy even in case of excessive carbohydrate intake in clinical settings. 34 Another study on empagliflozin concluded that empagliflozin increased expenditure of energy as well as production of heat and promotes fat utilization and browning. 22 In a clinical study involving 54 patients with uncontrolled T2DM, it was observed that administration of dapagliflozin (5 mg OD) for 6 months led to significant amelioration in glycemic control and significantly increased natural logarithmic transformed value of reactive hyperemia peripheral arterial tonometry (LnRHI). Furthermore, a significant reduction in total, subcutaneous, and abdominal visceral fat areas was also observed. 35 Another clinical study on dapagliflozin concluded that, when given concomitantly with pioglitazone, dapagliflozin can prevent pioglitazone-therapy related weight gain (Table 2 ).
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| EFFEC T OF SG LT2 INHIB ITOR S ON RENAL DISORDER S
Diabetes is one of the primary causes of end-stage renal disease and numerous patients of diabetes also suffer from some form of renal disorder. Various glucose-dependent pathways are responsible in the pathophysiological processes associated with diabetic nephropathy.
Recent studies have indicated that SGLT2 inhibitors show significant renoprotective effects which are believed to be caused due to the amalgamation of improved glycaemic control and other haemodynamic and non-haemodynamic pharmacodynamic actions of SGLT2 inhibitors on the renal system.
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An in vivo study on uninephrectomized db/db mice by Tang and colleagues concluded that treatment with dapagliflozin led to reversal in the elevation in albumin levels and markers of glomerulosclerosis. Furthermore, dapagliflozin also significantly reduced the expression of Nox2, Nox4, p47phox, MCP-1, and NF-kBp65 levels as well as urine TBARS levels in the kidney. Henceforth, a reduction in the progression of renal fibrosis was observed in the mice. 22 In another study on mice, it was found that treatment with dapagliflozin attenuated type 2 diabetes mellitus-induced Nlrp3/ASC inflammosome activation and suppressed the progression of diabetic nephropathy.
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Clinical studies, such as the EMPA-REG OUTCOME trial, also concluded that administration of empagliflozin suppressed the progression of chronic kidney disease which has been attributed to their site of action in the proximal tubules which leads to increased delivery of electrolytes and fluids to the macula densa, which in turn leads to a surge in tubular back pressure and reduces glomerular filtration rate as a result of activation of tubuloglomerular feedback. 39, 40 A meta-analysis encompassing 62 studies and comprising 34,941 patients concluded that all SGLT2
inhibitors significantly reduced serum uric acid levels when compared to control, therefore indicating a potential role of SGLT2
inhibitors for the treatment of hyperuricaemia. 41 The favourable effects of SGLT2 inhibitors leading to its renoprotective effect have been hypothesized to be caused as a result of diminution of intraglomerular pressure, modifications in local and systemic degree of activation of RAAS, and the aforementioned use of more efficient energy substrates (ketone bodies). 42 SGLT2 inhibitors have also been to found to protect renal tubular cells by protecting them from mitochondrial damage caused because of metabolic stresses, thereby revealing a novel mechanism of action. 43 Moreover, as far as diabetic and non-diabetic proteinuric renal diseases are concerned, angiotensin converting enzyme (ACE) inhibitors are the most effective and commonly prescribed drugs, however, it has been proposed that concomitant therapy with SGLT2 inhibitors can be used in those patients in which there is insufficient nephroprotection because of partial blockade of renin-angiotensin system by ACE inhibitors. 44 Hence, the favourable effects of SGLT2 inhibitors on the renal system make them the drugs of choice in patients with (and possibly without) diabetes-associated renal impairment. 
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